Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 5/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | CRHBP | P24387 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12261608 | 1.00 | TDP1 (0.43) | TDP1ALOX5SLC6A4MAPTKDM4E | |
| SCHEMBL1579401 | 1.00 | TDP1 (0.43) | TDP1ALOX5SLC6A4MAPTKDM4E | |
| Cadaverine Tartrate SCHEMBL2026631 | 0.84 | ALOX5 (0.41) | TDP1ALOX5MAPTKDM4EPOLB | |
| Cadaverine Tartrate SCHEMBL2026630 | 0.84 | ALOX5 (0.41) | TDP1ALOX5MAPTKDM4EPOLB | |
| SCHEMBL12626890 | 0.81 | MAPT (0.40) | TDP1ALOX5MAPTKDM4EESR2 | |
| SCHEMBL16446126 | 0.80 | TDP1 (0.42) | TDP1ALOX5MAPTKDM4EESR2 | |
| SCHEMBL16445660 | 0.80 | TDP1 (0.42) | TDP1ALOX5MAPTKDM4EESR2 | |
| SCHEMBL19158297 | 0.80 | TDP1 (0.42) | TDP1ALOX5MAPTKDM4EESR2 | |
| SCHEMBL18878114 | 0.78 | TDP1 (0.40) | TDP1ALOX5MAPTKDM4EESR2 | |
| SCHEMBL12261087 | 0.78 | AAK1 (0.37) | TDP1ALOX5MAPTKDM4EESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11945805-B2 | Inhibitors of CXCR2 | CHEMOCENTRYX, INC (US) | 2024-04-02 | — | — | US | disclosed |
| CN-108601766-B | CXCR2 inhibitors | 凯莫森特里克斯股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
| US-20220009911-A1 | INHIBITORS OF CXCR2 | CHEMOCENTRYX, INC. | 2022-01-13 | — | — | US | disclosed |
| US-11040960-B2 | Inhibitors of CXCR2 | CHEMOCENTRYX, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| EP-3377059-B1 | INHIBITORS OF CXCR2 | CHEMOCENTRYX INC (US) | 2020-10-21 | — | — | EP | disclosed |
| US-20200140418-A1 | INHIBITORS OF CXCR2 | CHEMOCENTRYX, INC. | 2020-05-07 | — | — | US | disclosed |
| US-10370363-B2 | Inhibitors of CXCR2 | CHEMOCENTRYX, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180170916-A1 | INHIBITORS OF CXCR2 | CHEMOCENTRYX, INC. | 2018-06-21 | — | — | US | disclosed |
| US-9809581-B2 | Inhibitors of CXCR2 | CHEMOCENTRYX, INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-20170144996-A1 | INHIBITORS OF CXCR2 | CHEMOCENTRYX, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20050137200-A1 | Potassium channel modulators; antiarrhythmia agents | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-06-23 | — | — | US | disclosed |
| US-6903216-B2 | Anthranilamides with heteroarylsulfonyl side chain, process of preparation, and use | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-06-07 | — | — | US | disclosed |
| EP-1399423-A2 | ANTHRANILIC ACID AMIDES WITH A HETEROARYLSULFONYL SIDE CHAIN, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS A MEDICAMENT OR DIAGNOSTIC AGENT AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS | Aventis Pharma Deutschland GmbH (DE) | 2004-03-24 | — | — | EP | disclosed |
| EP-1385820-A1 | ANTHRANILIC ACID AMIDES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS ANTIARRHYTHMIA AGENTS, AND PHARMACEUTICAL PREPARATIONS THEREOF | Sanofi-Aventis Deutschland GmbH (DE) | 2004-02-04 | — | — | EP | disclosed |
| US-20030187033-A1 | Anthranilamides and methods of their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-10-02 | — | — | US | disclosed |
| US-20030114499-A1 | Anthranilamides with heteroarylsulfonyl side chain, process of preparation, and use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-06-19 | — | — | US | disclosed |
| WO-2002100825-A2 | ANTHRANILIC ACID AMIDES WITH A HETEROARYLSULFONYL SIDE CHAIN, AND USE THEREOF AS ANTIARRHYTHMIC ACTIVE SUBSTANCES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-12-19 | — | — | WO | disclosed |
| WO-2002088073-A1 | ANTHRANILIC ACID AMIDES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS ANTIARRHYTHMIA AGENTS, AND PHARMACEUTICAL PREPARATIONS THEREOF | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220009911-A1 | INHIBITORS OF CXCR2 | CXCR2, CXCR3, CXCR1 | TDP1 4269/4885ALOX5 3187/4885SLC6A4 4533/4885 |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | CCR1, ACKR3, CXCR1 | TDP1 4014/4885ALOX5 428/4885SLC6A4 4197/4885 |
| US-20170144996-A1 | INHIBITORS OF CXCR2 | CXCR2, CXCR3, CXCR1 | TDP1 4269/4885ALOX5 3187/4885SLC6A4 4533/4885 |
| US-20200140418-A1 | INHIBITORS OF CXCR2 | CXCR2, CXCR3, CXCR1 | TDP1 4269/4885ALOX5 3187/4885SLC6A4 4533/4885 |
| US-10370363-B2 | Inhibitors of CXCR2 | CXCR2, CXCR3, CXCR1 | TDP1 4269/4885ALOX5 3187/4885SLC6A4 4533/4885 |
| US-20050137200-A1 | Potassium channel modulators; antiarrhythmia agents | KCNJ2, KCNQ5, KCNH1 | TDP1 4295/4885ALOX5 1666/4885SLC6A4 2452/4885 |
| US-11945805-B2 | Inhibitors of CXCR2 | CXCR2, CXCR3, CXCR1 | TDP1 4269/4885ALOX5 3187/4885SLC6A4 4533/4885 |
| US-11040960-B2 | Inhibitors of CXCR2 | CXCR2, CXCR3, CXCR1 | TDP1 4269/4885ALOX5 3187/4885SLC6A4 4533/4885 |
| US-20030114499-A1 | Anthranilamides with heteroarylsulfonyl side chain, process of preparation, and use | KCNJ2, KCNQ5, KCNH1 | TDP1 4564/4885ALOX5 975/4885SLC6A4 3262/4885 |
| US-20180170916-A1 | INHIBITORS OF CXCR2 | CXCR2, CXCR3, CXCR1 | TDP1 4269/4885ALOX5 3187/4885SLC6A4 4533/4885 |
| US-20030187033-A1 | Anthranilamides and methods of their use | KCNH1, KCNJ2, KCNH2 | TDP1 3404/4885ALOX5 1790/4885SLC6A4 4324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.